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Intravenous vaccination with radiation-attenuated 
sporozoites (RAS) of Plasmodium can provide solid pro-
tection against malaria (Nussenzweig et al. 1967). Im-
munity generated by vaccination with RAS sporozoites 
is targeted towards a dominant protective antigen, the 
circumsporozoite (CS) protein (Kumar et al. 2006). Nev-
ertheless, there exist other protective antigens yet to be 
characterised (Kumar et al. 2006, Mauduit et al. 2009). 
Following immunisation with RAS, the CS protein is rec-
ognised by antibodies and CD4+ and CD8+ T cells that can 
eliminate pre-erythrocytic stages of the parasite (Nardin 
et al. 1989, Romero et al. 1989, Malik et al. 1991, Rénia et 
al. 1991, Rodrigues et al. 1991). These results led to the de-
velopment of vaccine formulations aimed at eliciting high 
antibody titres against sporozoites and/or large numbers 
of CD4+ and CD8+ T cells specific for liver stage compo-
nents of malaria (reviewed by Bargieri et al. 2011).
Confirmation that the CS protein can be used for a 
human vaccine came from recent studies using the dead-
ly parasite Plasmodium falciparum. This vaccine formu-
lation consisted of a large C-terminal fragment of the CS 
protein fused to the antigen S of hepatitis B (convention-
al hepatitis B vaccine, Engerix B®) and was expressed 
as a recombinant protein in Saccharomyces cerevisiae. 
The fusion protein, named RTS, when expressed with 
antigen S, naturally assembles into virus-like particles 
called RTS,S. The efficacy of the RTS,S formulation de-
pended on the use of adjuvant systems (AS) consisting 
of two different formulations of monophosphoryl lipid 
A (a detoxified form of lipopolysaccharides) and QS21 
(saponin purified from Quillaja saponaria) in either an 
oil-in-water emulsion (AS02) or a liposomal suspension 
(AS01) (Cohen et al. 2010).
Recent Phase II trials in naïve human volunteers 
challenged with P. falciparum sporozoites found effica-
cies ranging from 32-50%. Immunological studies per-
formed on these vaccinated individuals indicated that 
protection correlated with the concentration of specific 
antibodies and the frequency of interferon gamma (IFN-
γ)-producing cells detected by enzyme-linked immuno-
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Recently, we described the improved immunogenicity of new malaria vaccine candidates based on the expression 
of fusion proteins containing immunodominant epitopes of merozoites and Salmonella enterica serovar Typhimu-
rium flagellin (FliC) protein as an innate immune agonist. Here, we tested whether a similar strategy, based on an 
immunodominant B-cell epitope from malaria sporozoites, could also generate immunogenic fusion polypeptides. 
A recombinant His6-tagged FliC protein containing the C-terminal repeat regions of the VK210 variant of Plasmo-
dium vivax circumsporozoite (CS) protein was constructed. This recombinant protein was successfully expressed 
in Escherichia coli as soluble protein and was purified by affinity to Ni-agarose beads followed by ion exchange 
chromatography. A monoclonal antibody specific for the CS protein of P. vivax sporozoites (VK210) was able to 
recognise the purified protein. C57BL/6 mice subcutaneously immunised with the recombinant fusion protein in the 
absence of any conventional adjuvant developed protein-specific systemic antibody responses. However, in mice 
genetically deficient in expression of TLR5, this immune response was extremely low. These results extend our previ-
ous observations concerning the immunogenicity of these recombinant fusion proteins and provide evidence that the 
main mechanism responsible for this immune activation involves interactions with TLR5, which has not previously 
been demonstrated for any recombinant FliC fusion protein.
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sorbent spot (Kester et al. 2009). A number of Phase IIb 
trials have been completed and others continue to be car-
ried out in the field. Although results from field trials are 
more difficult to interpret, studies performed in children 
in the endemic areas have shown between 49.5-62% ef-
ficacy in retarding the first malaria episode during the 
six-month period studied (Abdulla et al. 2008, Bejon et 
al. 2008). As protective immunity was found to be high-
ly dependent on the adjuvants used in the formulation, 
these studies highlight the importance of adjuvant devel-
opment for an effective malaria vaccine. Similar studies 
with the CS protein of Plasmodium vivax have been ini-
tiated but have not reported findings to date. 
Based on the ability of flagellin to efficiently induce 
humoral and cellular immune responses against foreign 
antigens, we explored the use of this molecule for the 
generation of fusion proteins containing malarial anti-
gens. For our initial studies, we selected the 19-kDa C-
terminal region of merozoite surface protein-1 (MSP-119) 
from P. vivax or P. faciparum. MSP-119 was fused to the 
C-terminal end of FliC flagellin from Salmonella ty- 
phimurium. This fusion protein was able to bind and ac-
tivate TLR5 expressed by in vitro-cultured transfected 
cells and it was recognised by serum from patients with 
P. vivax malaria. Moreover, the fusion protein was rec-
ognised by monoclonal antibodies against three-dimen-
sional structural epitopes of MSP-119, which indicated 
that it was correctly folded when expressed in Escheri-
chia coli (Bargieri et al. 2008, 2010).
We immunised mice and rabbits with recombinant 
fusion protein in the absence of additional adjuvant. Im-
munised animals developed strong, specific and long-
lasting antibody-mediated responses. Antibody titres 
after the second immunisation were similar to those 
following immunisation with recombinant MSP-119 
emulsified in complete/incomplete Freund’s adjuvant. 
Additionally, the antibodies generated by these immu-
nisations recognised P. vivax or P. falciparum merozo-
ites as detected by immunofluorescence (Bargieri et al. 
2008, 2010). Most importantly, rabbits injected with Pf-
MSP-119 fused to flagellin raised high antibody titres that 
dramatically inhibited the in vitro growth of the parasite 
lines 3D7, S20 and FCR3 (Bargieri et al. 2010).
In the absence of other adjuvant, the immune response 
following immunisation was biased toward a type 2 re-
sponse with a high IgG1/2 ratio and limited amounts of 
IFN-γ secretion by splenic immune cells. Nevertheless, the 
addition of other adjuvants to the fusion protein, such as a 
TLR-9 agonist, modulated the immune response towards a 
type 1 response with a lower IgG1/2 ratio and significantly 
greater secretion of IFN-γ (Bargieri et al. 2008). 
In this study, we have investigated the immunoge-
nicity of a fusion polypeptide containing the immu-
nodominant region of the CS protein from P. vivax and 
the innate immune agonist Salmonella Typhimurium 
FliC flagellin. The immunogenicity of the recombinant 
fusion protein was assessed by immunisation of mice 
with the recombinant protein alone. Additionally, we in-
vestigated whether the antibody response was dependent 
on expression of the TLR5 molecule.
MATERIALS AND METHODS
Generation of the recombinant protein His-
6FliC-PvCS-VK210 - Generation of the original 
plasmid has been described previously (Bargieri et 
al. 2008). The MSP-119 gene was removed by treat-
ment with the enzymes HindIII and XhoI. The syn-
thetic gene containing the sequence of nucleotides 
CAAGCTTGCGCAAGCGATATGGCGAAAAAA-
G A A AC C G T G T G G C G T C T G G A AG A AT T T-
GGCCGTTTCGATCGTGCAGATGGTCAGCCG-
GCAGGTGACCGCGCCGACGGTCAGCCGGCAG-
GTGATCGTGCAGCCGGTCAGCCGGCGGGT-
G AT C GT G CAG C G G G C CAG C C G G C G G GT-
GATCGCGCCGATGGTCAACCGGCCGGTGAT-
GACCGCGCCGATGGCCAACCGGCCGGTGAC-
C G C G C C G AT G GT CAG C C G G C C G G C G AC -
CGCGCCGCCGGCCAACCGGCCGGCGACCGCG-
CAGCCGGCCAACCGGCCGGTGATCGCGCA-
GATGGTCAGCCGGCCGGTGATTAACTCGAG was 
cloned into this vector. Regions in underlined font repre-
sent recognition sites for HindIII and XhoI. The recom-
binant protein was expressed and purified as described 
previously (Bargieri et al. 2008). Briefly, recombinant 
E. coli BL21 DE3 (Novagen) was cultivated at 37ºC in 
flasks containing Luria broth (LB) and kanamycin 
(30 µg/mL). Protein expression was induced at an OD600 
of 0.6 with 0.1 mM IPTG (Invitrogen) for 4 h. After cen-
trifugation, bacteria were lysed on ice with an ultrasonic 
processor (Sonics & Materials INC, Vibra Cell VCX 
750) in a phosphate buffer with 1.0 mg/mL lysozyme 
(Sigma) and 1mM PMSF (Sigma). Bacterial lysates 
were centrifuged and the supernatant was applied to a 
column containing Ni2+-NTA-agarose resin (Quiagen). 
After several washes, bound protein was eluted with 
0.5 M imidazole (Sigma). Eluted protein was dialysed 
against 20 mM Tris-HCl (pH 8.0) and the recombinant 
protein was purified by ion-exchange chromatography 
using a Resource Q column (GE Healthcare) coupled to 
an FPLC system (GE Healthcare). Fractions containing 
highly pure recombinant protein were pooled and exten-
sively dialysed against phosphate-buffered saline (PBS) 
(pH 7.2). Protein concentration was determined by the 
Bradford assay and by sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE) analyses.
FliC purification - Native Salmonella Typhimurium 
FliC was purified from the attenuated Salmonella Ty- 
phimurium SL3201 strain, which expresses FliC but not 
FljB (Bargieri et al. 2008). Briefly, bacteria were grown 
in LB supplemented with kanamycin (30 µg/mL) over-
night at 37ºC under aeration (80 rpm). Cells were washed 
once with PBS and submitted to mechanical shearing 
during four 2 min cycles in a bench vortex mixer. The 
cell suspensions were centrifuged to remove cellular 
debris and, following acetone precipitation, the flagel-
lar filaments were collected from the supernatant and 
suspended in PBS. The purity of the preparations was 
monitored by SDS-PAGE. 
Immunisation regimens - Six-eight-week-old female 
C57BL/6 (H-2b) or genetically deficient TLR5 (KO) 
(Feuillet et al. 2006) mice were purchased from the Fed-
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eral University of São Paulo (UNIFESP), Brazil. Mice 
were immunised subcutaneously three times each three 
weeks apart. The first immunisation was given in the hind 
footpads with a final volume of 50 µL in each footpad and 
the second and third immunisations were in the base of 
the tail in a final volume of 100 µL. For each immunisa- 
tion, 5 µg or 10 µg of fusion protein or FliC was used. 
Immunological assays - For immunologic charac-
terisation, proteins on SDS-PAGE gels were transferred 
electrophoretically onto nitrocellulose membranes (Mil-
lipore, CA, USA). The membranes were blocked for up 
to 1 h using nonfat milk in PBS (5% w/vol) and bovine 
serum albumin (2% w/vol) containing 0.1% Tween 20 
(PBS-T). After washing with 0.05% PBS-T, the blots 
were incubated for 1 h at room temperature with the ap-
propriate primary antibody diluted in PBS-T. The prima-
ry antibodies used were the following: (i) mouse mono-
clonal antibodies (MAb) to His6 (Amersham/GE) diluted 
1:1,000, (ii) MAb 2F2 to PvCS protein from the VK210 
strain (1 µg/mL) (Nardin et al. 1982) and (iii) MAb to 
PvCS protein from the VK247 strain. After washing, 
peroxidase-labeled goat anti-mouse IgG (Sigma, St. 
Louis, Mo) diluted 1:1,000 was added for 1 h. The blots 
were then washed and developed with diaminobenzidin 
solution (0.285 mg/mL, Sigma).
Serum anti-PvCS antibodies were detected by en-
zyme linked immunosorbent assay (ELISA) as de-
scribed previously (Bargieri et al. 2008). Recombinant 
His6PvCS protein (200 ng/well) was used as the solid 
phase-bound antigen. This recombinant protein contains 
the entire PvCS protein, including the N and C-terminal 
portions and repeats (VK210) and further information 
will be published in detail elsewhere. Mouse sera were 
tested at serial dilutions starting at 1:200 and a peroxi-
dase-conjugated goat anti-mouse IgG (Sigma) was ap-
plied at a final dilution of 1:1,000. Anti-PvCS antibody 
titres were determined for the highest dilution yielding 
an OD492 greater than 0.1. The results are presented as 
mean ± standard deviation.
Statistical analyses - The one-way analysis of vari-
ance (ANOVA), Student’s t test, Tukey honestly signifi-
cant difference test and Kruskal-Wallis ANOVA were 
used to compare the differences between the mean val-
ues of the tested immunisation groups.
Ethics - The use of animals and the experimental pro-
cedures, including the number of mice per experimental 
group, have been approved by the Ethics Committee for 
Animal Care of the UNIFESP (Id # CEP 0307/09). 
RESULTS
Production and purification of flagellin fusion protein 
- We generated a recombinant fusion protein containing a 
hexa-histidine tag (His6) consisting of the immunodomi-
nant region of the PvCS protein (VK210 strain) linked 
to the C-terminal end of FliC (His6FliC-PvCS-VK210). 
The schematic representations of the recombinant poly-
peptide and purified protein are presented in Fig. 1A, B, 
respectively. The purified protein migrated under dena-
tured and reduced condition as a main band of ~65 kDa 
and a larger band of ~130 kDa. Both bands were deter-
mined to be recombinant protein by the recognition of 
the His6 MAb (Fig. 1B, Lanes 3, 4). The larger band most 
likely represents a dimeric form of the recombinant pro-
tein. The native FliC protein purified from monophasic 
Salmonella Typhimurium of strain SL3201 migrated as 
predicted at ~49 kDa (Fig. 1B, Lane 1) and was used as a 
control in immunologic assays.
To determine whether the fusion polypeptide re-
tained the ability to be recognised by the MAb 2F2 
specific for the immunodominant epitope of the PvCS 
protein of strain VK210, we performed ELISA and im-
munoblot assays. This MAb recognised the recombinant 
protein in both assays. Fig. 1B, Lane 6 shows the im-
munoblot confirming recognition of the recombinant 
protein His6FliC-PvCS-VK210 by MAb 2F2 (Nardin et 
al. 1982). This epitope was not recognised by a MAb to 
the immunodominant epitope of the PvCS protein from 
strain VK247 (Fig. 1B, Lane 8). In control experiments, 
this MAb recognised the PvCS protein from the VK247 
strain (LHT, unpublished observations). 
Induction of PvCS protein-specific antibody re-
sponses in mice immunised with His6FliC-PvCS-VK210 - 
The serum IgG responses to PvCS protein of the VK210 
strain were determined in C57BL/6 mice immunised 
subcutaneously with purified His6FliC-PvCS-VK210 
protein (5 µg/dose/mouse). Mice parenterally immunised 
with the recombinant protein developed significant lev-
els of specific IgG titres. Maximal IgG antibody titres 
were achieved after the second immunisation (Fig. 2), as 
a third immunising dose was not found to improve anti-
body titres (p > 0.05). These titres were maintained for 
15 weeks (9 weeks after the third dose) (Fig. 2). 
TLR5-dependence on PvCS protein-specific antibody 
responses in mice immunised with His6FliC-PvCS-VK210 
- Because FliC activates a variety of innate pattern-asso-
Fig. 1: generation and characterisation of recombinant Plasmodium 
vivax circumsporozoite protein VK 210 strain. A: schematic represen-
tation of the recombinant protein used in the present study; B: sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblot analysis of the recombinant protein. Lanes 1, 2: SDS-
PAGE of purified Salmonella Typhimurium FliC flagellin and His6-
FliC-PvCS-VK210 proteins, respectively; 3, 4: immunoblot of the same 
two proteins described in Lanes 1, 2 probed with a mouse monoclonal 
antibodies (MAb) to His6; 5, 6: immunoblot of the same two proteins 
described in Lanes 1, 2 probed with a MAb to repeats of PvCS protein 
VK210 strain; 7, 8: immunoblot of the same two proteins described in 
Lanes 1, 2 probed with a MAb to repeats of PvCS protein VK247 strain. 
Each Lane was loaded with approximately 1 µg of protein separated on 
a 15% SDS-PAGE and stained with Coomassie Blue (Lanes 1, 2). 
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ciated receptors during the immune response to flagellin 
(Sanders et al. 2009, Mizel & Bates 2010, Vijay-Kumar et 
al. 2010), we sought to determine whether TLR5 was par-
ticularly important for this process in response to immu-
nisation. To this end, we immunised WT C57BL6 mice or 
TLR5 KO mice with His6FliC-PvCS-VK210. Three weeks 
after the second dose, we evaluated serum antibody titres 
in these animals. As shown in Fig. 3, the antibody titres 
from immunised TLR5 KO mice represented only 3.24% 
of the titres detected from WT immunised mice. These 
results unequivocally demonstrate that the main route for 
immune activation following immunisation with our fu-
sion recombinant protein was via TLR5. 
DISCUSSION
In the present study, we tested whether a straight-
forward and inexpensive fusion protein containing the 
prototypic innate immune activator FliC from Salmo-
nella and an immunodominant epitope from the ma-
laria sporozoite could elicit specific humoral immune 
responses to the CS protein, the best-studied malaria 
vaccine candidate. From our studies, we concluded 
that parenteral immunisation with the fusion protein 
His6FliC-PvCS-VK210 elicited specific adaptive immune 
responses in vaccinated mice.
Various systems using flagellin components as 
carriers or adjuvants for fusion proteins containing re-
combinant antigens have been described in the last few 
years. A detailed review of these data was very recently 
published (Mizel & Bates 2010). Most importantly for 
vaccine development, the influenza vaccine candidate 
VAX125, which consists of an influenza antigen fused 
to flagellin, was given a complete Phase I clinical trial 
that tested safety, reactivity, immunogenicity, toleroge-
nicity and escalating dose-range. The results from this 
trial showed recombinant flagellin to be generally well-
tolerated by vaccinated individuals. Importantly, 91% of 
individuals receiving any dose of recombinant protein 
developed titres of neutralising antibodies compatible 
with protective status against influenza infection (clini-
caltrials.gov/NCT00921947) (Treanor et al. 2010).
The immunogenicity of our recombinant protein was 
independent of the use of conventional adjuvants, which 
led us to hypothesise that the main adjuvant activity seen 
was due to the innate immune agonist FliC. Previous 
studies have shown flagellin to activate multiple pattern-
associated molecules such as TLR5 and NLRC4 (also 
known as Ipaf) (Sanders et al. 2009, Mizel & Bates 2010, 
Vijay-Kumar et al. 2010), which had made it difficult to 
determine the precise nature of the adjuvant activity using 
single KO mice (Sanders et al. 2009, Vijay-Kumar et al. 
2010). Only very recently, by using double KO mice lack-
ing both TLR5 and NLRC4, it was possible to demon-
strate the contribution of these molecules to the adjuvant 
activity of flagellin when admixed to ovalbumin (Vijay-
Kumar et al. 2010). We were able to decipher the main 
adjuvant contribution as originating at TLR5 because the 
TLR5 KO mice displayed significantly impaired immune 
responses after vaccination (Fig. 3). One likely explana-
tion for such dominance of the TLR5 pathway comes 
from a very recently published article that found the ad-
juvant activity of flagellin to rely on the ability of TLR5 
to function as an endocytic receptor and thereby enhance 
specific immune responses (Letran et al. 2011).
 Another possible explanation for this dominance of 
the TLR5 pathway is that the NLRC4 activation domain 
of flagellin is possibly disrupted or blocked by the pres-
ence of the malarial epitope in the recombinant fusion 
protein. The NLRC4 activation domain is located at the 
D0 domain of FliC and requires the most C-terminal 
35 AA of the protein. Therefore, the introduction of the 
malarial epitope may result in a domain that is no lon-
ger functional (Lightfield et al. 2008). Alternatively, the 
recombinant flagellin may not be capable of transloca-
tion to the cell cytoplasm where NLRC4 activation takes 
place. It will be important in the future to determine why 
this recombinant protein lost the ability to efficiently ac-
tivate NLRC4; in the meantime, it can be a useful tool to 
study TLR5 activation by flagellin that is independent of 
the activation of NLRC4. 
In summary, the present study has reproduced and ex-
tended upon our recent reports on the use of Salmonella 
flagellin as an adjuvant and antigen carrier to allow for 
Fig. 2: detection of total IgG responses to His6-PvCS-VK210 in serum 
samples of immunised mice. Female C57BL/6 mice were immunised 
three times with 5 µg of the purified Salmonella Typhimurium FliC 
flagellin or His6-FliC-PvCS-VK210 proteins antibody titres were de-
tected by conventional enzyme linked immunosorbent assay. Data are 
representative of two experiments using five mice per group.
Fig. 3: TLR5-dependence of total IgG responses to His6-PvCS-VK210 
in serum samples of immunised mice. Female WT C57BL/6 or TLR5 
KO mice were immunised twice with 10 µg of the purified His6-FliC-
PvCS-VK210 protein. Antibody titres were detected by conventional 
enzyme linked immunosorbent assay. Antibody titres of TLR5 KO 
were significantly lower than WT mice (p < 0.001). Data are repre-
sentative of two experiments using five mice per group.
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additional plasticity in the design and production of vac-
cine antigens endowed with enhanced immunogenicity for 
important malarial antigens. Considering the results from 
recent studies in humans, our findings strongly argue in 
favour of implementation of future clinical trials. In ad-
dition, the present study has dissected important mecha-
nistic information on the immunostimulatory properties 
of these immunisations by showing that TLR5 is the pri-
mary receptor activated by our recombinant protein. 
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